DeepMed Research

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

YOLT-201

Generic Name: YOLT-201

Overview

No overview information available.

Background

No background information available.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

A Phase I/IIa，Open-label, Single Ascending Dose and Dose-expansion Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of YOLT-201 in Patients With Transthyretin Amyloidosis Polyneuropathy (ATTR-PN) or Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)

Phase 1

Recruiting

Posted: 2024/08/06

Sponsor:

YolTech Therapeutics...

Efficacy and Safety of Intravenous YOLT-201 for Transthyretin Amyloidosis Cardiomyopathy

Early Phase 1

Recruiting

Posted: 2023/10/13

Sponsor:

Zhejiang University

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

Yoltech Therapeutics' YOLT-201 Shows Promise in Phase I ATTR Amyloidosis Trial

5 months ago

Yoltech Therapeutics' YOLT-201, a CRISPR/Cas9-based gene-editing therapy, demonstrated robust safety and tolerability in a Phase I/IIa trial for ATTR amyloidosis.

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy